Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Warts - Pipeline Review, H2 2016, provides an overview of the Genital Warts (Infectious Disease) pipeline landscape.

Genital warts (condyloma acuminata) are one of the most common types of sexually transmitted infections. Genital warts are caused by the human papillomavirus (HPV). Symptoms include small, flesh-colored or gray swellings in genital area, itching or discomfort in genital area, pain during intercourse and frequent urination. Treatment includes antiviral drugs and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Genital Warts - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Genital Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Genital Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Warts (Condylomata Acuminata) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 8, 1, 4 and 2 respectively for Genital Warts.

Genital Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Warts (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Genital Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Genital Warts (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Genital Warts (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Genital Warts (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Genital Warts (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Genital Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Genital Warts (Condylomata Acuminata) Overview 7
Therapeutics Development 8
Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview 8
Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies 9
Genital Warts (Condylomata Acuminata) - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Genital Warts (Condylomata Acuminata) - Products under Development by Companies 12
Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development 13
Agilvax, Inc. 13
Aviragen Therapeutics, Inc. 14
Biogenomics Limited 15
BioMAS Ltd. 16
Cutanea Life Sciences Inc 17
Foamix Pharmaceuticals Ltd. 18
G&E Herbal Biotechnology Co., Ltd. 19
Laboratories Ojer Pharma S.L. 20
LEO Pharma A/S 21
Novan, Inc. 22
Novartis AG 23
Tamir Biotechnology, Inc. 24
Zydus Cadila Healthcare Limited 25
Genital Warts (Condylomata Acuminata) - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
AX-03 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
BTA-074 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
CB-0602 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
human papillomavirus vaccine - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
imiquimod - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
imiquimod SR - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
ingenol mebutate - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
interferon alfa-2b - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
LFX-453 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
omiganan pentahydrochloride - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
PP-210 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
ranpirnase - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
SB-206 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
SRT-100 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Genital Warts (Condylomata Acuminata) - Dormant Projects 58
Genital Warts (Condylomata Acuminata) - Discontinued Products 59
Genital Warts (Condylomata Acuminata) - Product Development Milestones 60
Featured News & Press Releases 60
May 10, 2016: Novan to Present Anti-viral Data for Nitric Oxide Product Candidate SB206 60
May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables

Number of Products under Development for Genital Warts (Condylomata Acuminata), H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Genital Warts (Condylomata Acuminata) - Pipeline by Agilvax, Inc., H2 2016 13
Genital Warts (Condylomata Acuminata) - Pipeline by Aviragen Therapeutics, Inc., H2 2016 14
Genital Warts (Condylomata Acuminata) - Pipeline by Biogenomics Limited, H2 2016 15
Genital Warts (Condylomata Acuminata) - Pipeline by BioMAS Ltd., H2 2016 16
Genital Warts (Condylomata Acuminata) - Pipeline by Cutanea Life Sciences Inc, H2 2016 17
Genital Warts (Condylomata Acuminata) - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 18
Genital Warts (Condylomata Acuminata) - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2016 19
Genital Warts (Condylomata Acuminata) - Pipeline by Laboratories Ojer Pharma S.L., H2 2016 20
Genital Warts (Condylomata Acuminata) - Pipeline by LEO Pharma A/S, H2 2016 21
Genital Warts (Condylomata Acuminata) - Pipeline by Novan, Inc., H2 2016 22
Genital Warts (Condylomata Acuminata) - Pipeline by Novartis AG, H2 2016 23
Genital Warts (Condylomata Acuminata) - Pipeline by Tamir Biotechnology, Inc., H2 2016 24
Genital Warts (Condylomata Acuminata) - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 25
Assessment by Monotherapy Products, H2 2016 26
Number of Products by Stage and Target, H2 2016 28
Number of Products by Stage and Mechanism of Action, H2 2016 30
Number of Products by Stage and Route of Administration, H2 2016 32
Number of Products by Stage and Molecule Type, H2 2016 34
Genital Warts (Condylomata Acuminata) - Dormant Projects, H2 2016 58
Genital Warts (Condylomata Acuminata) - Discontinued Products, H2 2016 59